Prevalence of Orofacial Mucormycosis in Coronavirus Disease-2019 Patients: Insights from a Tertiary Care Center in Northern India
Authors:
- 30 May 2024
- journal article
- research article
- Published by Medknow in Indian Journal of Medical Specialities
- Vol. 15 (3) , 189-192
Abstract
Introduction: The severe acute respiratory syndrome coronavirus 2 that is the cause of the coronavirus disease-2019 (COVID-19) pandemic is linked to a variety of opportunistic bacterial and fungal coinfections. Orofacial mycoses, fungal infections affecting the oral and facial regions, have recently gained attention as potential complications in individuals with COVID-19. Materials and Methods: This study aims to contribute to the understanding of orofacial mucormycosis in the context of COVID-19, particularly focusing on the prevalence among patients in a tertiary care center in Northern India. This study comprised respiratory materials from 255 COVID-19 patients treated at Max Hospital, Saket. The laboratory received specimens for microbiological pneumonia workup culture and molecular detection. Results: The most prevalent site for mucormycosis was the rhino-orbital region, accounting for a majority of cases at 58.2%. Following the rhino-orbital region, the involvement extended to the rhino-orbital-cerebral region in a notable proportion of cases. Pulmonary sites were identified as a significant location for mucormycosis, though less frequent compared to the rhino-orbital region. Mucormycosis diagnoses were predominantly made using direct microscopy, with 82.6% (196/255) of patients undergoing this diagnostic method. Conclusion: Our study in Northern India revealed a high prevalence of orofacial mucormycosis in middle-aged diabetic males, often with a history of COVID-19 hospitalization and steroid use. Rhizopus spp. were the most common Mucorales identified, with treatment challenges due to antifungal resistance. Molecular tests, such as matrix-assisted laser desorption ionization–time of flight, are valuable for species identification, emphasizing the need for heightened awareness during the COVID-19 pandemic.Keywords
This publication has 17 references indexed in Scilit:
- Utility of Itraconazole and Terbinafine in Mucormycosis: A Proof-of-Concept AnalysisJournal of Investigative Medicine, 2022
- Risk factors for Coronavirus disease-associated mucormycosisJournal of Infection, 2021
- Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the WorldMycopathologia, 2021
- ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countriesMycoses, 2021
- Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in IndiaDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021
- A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in IndiaClinical Microbiology and Infection, 2020
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research ConsortiumThe Lancet Infectious Diseases, 2019
- Estimated burden of fungal infections in GermanyMycoses, 2015
- How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?Clinical Infectious Diseases, 2012
- ZygomycosisInfectious Disease Clinics of North America, 2002